Short-term mortality was 6.7% in men vs 9.0% in women for STEMI (p=0.05), 4.7% vs 4.2% for NSTEMI (p=0.67) and 5.2% vs 6.6% for UA (p=0.29). Middle-term mortality was 7.4% in men and 8.5% in women for STEMI (p=0.39), 11.5% vs 11.9% for NSTEMI (p=0.82) and 8.6% vs 10.9% for UA (p=0.20). The small higher short-term and middle-term mortality in women was removed after adjustment for age and center. In men the middle-term risk of death for STEMI compared with the corresponding population was 3.05 [2.32-4.02] in HG, 2.88 [2.25-3.68] in BR and 2.34 [1.83-2.99] in Lille. In women the risk of death was 6.80 [4.03-11.5], 5.04 [3.04-8.37] and 6.40 [4.28-9.58] in HG, BR and Lille respectively. Considering males and females together, middle-term mortality of STEMI for HG was in relation to the regional population 3.26 [2.56-4.15] and to the French population 4.17 [3.27-5.32], for BR 3.53 [2.83-4.41] vs 3.74 [6.00-4.67] and for Lille 4.40 [3.57-5.43] vs 3.42 [2.78-4.22]. Short-term and middle-term mortality were similar in men and women. In patients surviving an ACS, middle-term mortality was, comparatively to the corresponding population, from 2 to 3 times higher in women than in men.